Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study. (PubMed, Haematologica) - Sep 4, 2026 - "Corresponding two-year OS rates were 18.8%, 12.9%, and 4.5%. Overall response rates were 70.2% versus 36.8% (GIL+AZA vs AZA, nominal p."
Journal • P3 data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • FLT3
|
|
Anne-Marie Watson; Bhavik J Pandya; Caroline Chen; Elzbieta Patkowska; Eunice S Wang; Hassan Sibai; Jason E Hill; Je-Hwan Lee; Jessica K Altman; Jordi Esteve; Kamel Laribi; Mark D Minden; Michael Heuser; Monica Fumagalli; Nahla Hasabou; Pau Montesinos; Stanley C Gill; Tomoki Naoe; Violaine Havelange; Wen-Chien Chou
|